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Transcription factor, nuclear factor 
 
 
 
B (NF-
 
 
 
B), is required for osteoclast formation in vivo 
and mice lacking both of the NF-
 
 
 
B p50 and p52 proteins are osteopetrotic. Here we 
address the relative roles of the two catalytic subunits of the I
 
 
 
B kinase (IKK) complex that 
mediate NF-
 
 
 
B activation, IKK
 
 
 
 and IKK
 
 
 
, in osteoclast formation and inflammation-
induced bone loss. Our findings point out the importance of the IKK
 
 
 
 subunit as a 
transducer of signals from receptor activator of NF-
 
 
 
B (RANK) to NF-
 
 
 
B. Although IKK
 
 
 
 is 
required for RANK ligand-induced osteoclast formation in vitro, it is not needed in vivo. 
However, IKK
 
 
 
 is required for osteoclastogenesis in vitro and in vivo
 
.
 
 IKK
 
 
 
 also protects 
osteoclasts and their progenitors from tumor necrosis factor 
 
 
 
–induced apoptosis, and its 
loss in hematopoietic cells prevents inflammation-induced bone loss.
 
Bone development and remodeling are highly
regulated processes that involve synthesis of
bone matrix by osteoblasts and coordinated
bone resorption by osteoclasts (1). Osteo-
blasts originate from mesenchymal stem cells,
whereas osteoclasts are derived from hemato-
poietic monocyte/macrophage precursors (1).
Imbalanced osteoclast and osteoblast forma-
tion, activity, or survival can be caused by a
variety of hormonal changes or perturbed pro-
duction of inflammatory cytokines and growth
factors, and result in skeletal abnormalities that
are characterized by decreased (osteoporosis)
or increased (osteopetrosis) bone mass (1). In-
creased osteoclast formation and activity is ob-
served in many osteopenic disorders, including
postmenopausal osteoporosis (2), lytic bone
metastasis, or rheumatoid arthritis (3), and leads
to accelerated bone resorption and crippling
bone damage.
During osteoclast differentiation, osteo-
blastic/stromal cells provide a physical support
for nascent osteoclasts and produce soluble and
membrane-associated factors, such as macro-
phage-colony stimulating factor (M-CSF), and
receptor activator of NF-
 
 
 
B ligand (RANKL)
(4). RANKL (also called tumor necrosis factor–
related activation-induced cytokine, osteoclast
differentiation factor, osteoprotegerin ligand) is
a member of the TNF cytokine family and
an essential inducer of osteoclastogenesis and
bone remodeling through its receptor RANK,
a TNF-receptor (TNFR) family member (5,
6). Mice with a disrupted 
 
Rankl
 
 gene exhibit
severe osteopetrosis (6, 7). Disruption of the
 
Rank
 
 gene also results in lack of osteoclasts and
ensuing osteopetrosis (8). Similar to RANKL,
TNF-
 
 
 
 is a potent osteoclastogenic factor that
enhances proliferation and differentiation of
osteoclast precursors through its type I receptor
(TNFR1; reference 9). However, it remains
controversial whether TNF
 
 
 
 promotes osteo-
clastogenesis independently of RANKL (10,
11). RANK, like most other TNFR family
members, including TNFR1, transduces its
biochemical signals through recruitment of in-
tracellular signal transducers, called TNF recep-
tor-associated factors, which lead to activation
of NF-
 
 
 
B and mitogen-activated protein kinase
effector pathways (12–15). The relevance of
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these pathways to osteoclastogenesis is underscored by the
osteopetrotic phenotypes of mice lacking TNF receptor–
associated factor 6 (16); the NF-
 
 
 
B1/p50 and NF-
 
 
 
B2/p52
subunits of NF-
 
 
 
B (15, 17); or c-Fos (18), a component of
the AP-1 transcription factor, whose expression is mitogen-
activated protein kinase dependent (19).
NF-
 
 
 
B is a collection of dimeric transcription factors
that recognize similar DNA sequences called 
 
 
 
B sites. In
mammals there are five NF-
 
 
 
B proteins: cRel, RelA and
RelB, as well as NF-
 
 
 
B1/p50 and NF-
 
 
 
B2/p52. Although
the Rel proteins contain transcriptional activation domains,
such domains are absent in p50 and p52, whose activation
function depends on heterodimerization with any of the
three Rel proteins (20). As mentioned above, ablation of
p50 and p52 results in a severe osteopetrotic phenotype,
which most likely is due to the poor DNA binding activity
of the remaining NF-
 
 
 
B subunits (15). NF-
 
 
 
B proteins re-
side in the cytoplasm of nonstimulated cells but rapidly enter
the nucleus upon cell stimulation (21). This process, called
NF-
 
 
 
B activation, depends on two pathways. The classic
NF-
 
 
 
B signaling pathway involves activation of the I
 
 
 
B ki-
nase (IKK) complex that phosphorylates the inhibitors of
NF-
 
 
 
B (I
 
 
 
Bs) and targets them to ubiquitin-dependent deg-
radation (21). The I
 
 
 
Bs retain most NF-
 
 
 
B dimers, with the
exception of p52:RelB dimers, in the cytoplasm by masking
their nuclear localization signals (21). The alternative NF-
 
 
 
B
signaling pathway is responsible for activation of p52:RelB
dimers, which are generated by processing of cytoplasmic
p100:RelB dimers (21).
Currently, it is not entirely clear which of the two NF-
 
 
 
B activation pathways plays the dominant role in osteoclas-
togenesis. The IKK complex that is responsible for activation
of the canonical NF-
 
 
 
B pathway consists of two catalytic
subunits, IKK
 
 
 
 and IKK
 
 
 
, and a regulatory subunit, IKK
 
 
 
/
NF-
 
 
 
B essential modulator (22). Gene disruption experi-
ments demonstrated that IKK
 
 
 
 and IKK
 
 
 
 are important for
I
 
 
 
B phosphorylation and degradation, whereas IKK
 
 
 
 has
different and nonoverlapping functions (21). Importantly,
IKK
 
 
 
 forms homodimers, not associated with IKK
 
 
 
, that are
required for phosphorylation-induced p100 processing and
activation of the alternative pathway (23). Activation of the
alternative pathway also depends on the IKK
 
 
 
-phosphory-
lating kinase, NF-
 
 
 
B–inducing kinase (NIK; refereneces 23,
24). It was observed that NIK-deficient osteoclast precursors
do not respond to RANKL in an in vitro differentiation sys-
tem that is devoid of osteoblasts (25). However, 
 
aly
 
 mice,
which carry a point mutation in the 
 
Nik
 
 gene that prevents
NIK activation, are not osteopetrotic (26); osteopetrosis also
was not reported for 
 
Nik
 
 
 
/
 
 
 
 
 
mice (25). More recently, a
peptide inhibitor of IKK, which prevents the association of
IKK
 
 
 
 with IKK
 
 
 
, and therefore, blocks activation of the
classic pathway without affecting the alternative pathway,
was shown to prevent inflammation-induced bone loss in
vivo (27). These results suggest that the classic pathway is of
greater importance for osteoclastogenesis. To determine the
relative roles of the two pathways in osteoclastogenesis and
inflammation-induced bone loss, we undertook a genetic
approach based on the use of mouse strains that carry specific
mutations in the 
 
Ikk
 
 
 
 and 
 
Ikk
 
 
 
 genes. We found that IKK
 
 
 
,
but not IKK
 
 
 
, is essential for inflammation-induced bone
loss and is required for osteoclastogenesis in vivo. However,
the main function of IKK
 
 
 
 in osteoclastogenesis is to pre-
vent TNF
 
 
 
-induced apoptosis of osteoclast precursors. Once
TNF
 
 
 
-induced apoptosis is prevented through deletion of
the 
 
Tnfr1
 
 gene, IKK
 
 
 
 is no longer required for induction of
inflammation-induced bone loss, but it is still needed for
basal osteoclast function.
 
RESULTS
RANKL-induced in vitro osteoclastogenesis requires 
IKK
 
 
 
 and IKK
 
 
 
To determine the roles of the IKK catalytic subunits in os-
teoclastogenesis, we used mice that carry mutant forms of ei-
ther subunit—
 
Ikk
 
 
 
AA
 
 and 
 
Ikk
 
 
 
 
 
 mice. 
 
Ikk
 
 
 
AA
 
 mice are ho-
mozygous for a knock-in mutant allele, in which the
activation loop serines of IKK
 
 
 
—whose phosphorylation is
required for its activation (28)—were replaced with alanines;
this prevents IKK
 
 
 
 activation by upstream stimuli, including
RANK (29) and NIK (23). 
 
Ikk
 
 
 
AA
 
 mice are viable, healthy,
and fertile. These mice exhibit defective organization of sec-
ondary lymphoid organs and B cell maturation (30), a defect
that is very similar to what was found in 
 
Nik
 
 
 
/
 
 
 
 (31) or
 
Nik
 
aly/aly
 
 (26) mice. Ikk   mice were generated by crossing
Ikk F/F mice, homozygotes for a “floxed” Ikk  allele (32),
with Mx1-Cre transgenic mice that express Cre recombinase
from the IFN-inducible Mx-1 promoter (33). Injection of
polyinosinic-polycytidylic acid (poly[IC]), which induces
IFN production, into Ikk F/F:Mx1-Cre mice results in effi-
cient deletion of the floxed third exon of the Ikk  gene and
generation of IKK -deficiency in IFN-responsive cells, in-
cluding myeloid cells (34). To determine whether defective
Figure 1. Ikk AA and Ikk   BM cells exhibit defective RANKL-
mediated osteoclastogenesis in vitro. Equal numbers of BM cells were 
isolated from WT, Ikk AA, and Ikk   mice and cultured in the presence of 
M-CSF (10 ng/ml) alone or M-CSF plus RANKL (50 ng/ml). Osteoclastogenesis 
was monitored after 7 d by TRAP staining (red color). Note the giant cells 
that appear after incubation of WT BM with M-CSF and RANKL.JEM VOL. 201, May 16, 2005 1679
ARTICLE
IKK  activation or complete loss of IKK  affect osteoclasto-
genesis, we first used an in vitro differentiation system. BM
hematopoietic progenitors that were isolated from WT,
Ikk AA, and Ikk   mice were incubated with M-CSF and
RANKL for 7 d, and stained for tartrate-resistant acid phos-
phatase (TRAP), a marker for osteoclasts. Wt cultures
showed robust osteoclastogenesis and formed giant TRAP-
positive cells, whereas osteoclast formation was absent in
Ikk AA and Ikk   cultures (Fig. 1). Expression of several other
osteoclast markers, including CatK and matrix metallopro-
teinase-9, also was defective in RANKL-treated Ikk AA and
Ikk   BM cultures (unpublished data). These results suggest
that IKK  and IKK  are required for, and play nonredun-
dant roles in, M-CSF and RANKL-induced osteoclastogen-
esis in vitro.
RANKL-mediated NF- B activation is impaired in Ikk  , 
but not Ikk AA, osteoclast progenitors
To gain insights into the possible mechanisms by which
IKK  and IKK  promote osteoclastogenesis in vitro, we ex-
amined RANKL-induced NF- B activation in Ikk AA and
Ikk   BM cultures. BM-derived precursors from WT,
Ikk AA, and Ikk   mice were incubated with M-CSF and
RANKL and analyzed for expression of IKK  and IKK  by
immunoblot analysis (Fig. 2 A). As expected, no IKK  pro-
tein was detectable in Ikk   BM cells. Interestingly, the dele-
tion of IKK  also resulted in slightly decreased levels of
IKK  (Fig. 2 A); this suggests that IKK :IKK  complexes
or IKK  homodimers are not as stable as the heterotrimeric
IKK :IKK :IKK  complexes (22). Electrophoretic mobility
shift assays revealed marked induction of NF- B DNA bind-
ing activity in response to RANKL treatment in WT and
Ikk AA cultures, but only a weak response in Ikk   cultures
(Fig. 2 B). Similarly, RANKL activated IKK in WT and
Ikk AA cultures, but no IKK activity could be detected be-
fore or after RANKL treatment of Ikk   BM cells (Fig. 2 C).
In addition, RANKL induced the nuclear translocation of all
three Rel proteins in WT cells; this response was slightly re-
duced for RelB and cRel, but not for RelA, in Ikk AA cells
(Fig. 2 D). By contrast, the basal level of all three Rel pro-
teins in the nucleus and their RANKL-induced nuclear
translocation were diminished severely in Ikk   cultures. Al-
though IKK  plays a minor role in NF- B activation, other
experiments that were conducted with Ikk AA BM cells re-
vealed its requirement for induction of NF- B2/p100 pro-
cessing to p52 in response to RANKL (Fig. 2 E), as previ-
ously shown for several other TNF family members (30).
Defective osteoclastogenesis in Ikk   but not Ikk AA mice
To determine if IKK  and IKK  play a role in osteoclasto-
genesis in vivo, bones from 4 mo-old Ikk AA and Ikk  
mice were analyzed. To study the role of IKK  in bone de-
velopment we induced deletion of the Ikk  gene in Ikk F/F:
Mx1-Cre mice 9 d after birth. Histologic and histomorpho-
metric analyses of long bone (tibias) sections from Ikk AA
mice revealed no differences compared with WT bones, and
no alterations were found in trabecular size and distribution
or in the number of osteoclasts as determined by TRAP
staining (Fig. 3 A–C). These results suggest that basal osteo-
clastogenesis is not affected by the loss of IKK  activation in
vivo. By contrast, Ikk   mice showed an osteopetrotic phe-
notype. Ikk   mice are smaller and have a hunched back
compared with their Ikk F/F littermates (unpublished data).
Histologic analysis of tibias from these mice showed in-
creased trabecular size and distribution which resulted in
obliteration of the bone marrow cavity compared with
Ikk F/F littermates or WT mice of the same age (Fig. 3 A).
TRAP staining showed a greatly reduced number of osteo-
clasts in Ikk   bones (Fig. 3, B and C). Furthermore, quanti-
tative histomorphometric analyses of Ikk   bones revealed a
significant increase in bone volume due to increased trabec-
ular number compared with bones of WT littermates (Fig. 3
Figure 2. Biochemical analysis of RANKL signaling to NF- B in 
Ikk AA and Ikk   osteoclast progenitors. (A) Western blot analysis of 
protein extracts from WT, Ikk AA, and Ikk   osteoclast precursors stimu-
lated with RANKL for the indicated times. Immunoblot analysis was per-
formed with anti-IKK , anti-IKK , anti-I B , and anti-p38 (as loading 
control) antibodies. (B) NF- B DNA binding activity was assayed at the 
indicated times in RANKL-stimulated WT, Ikk AA, and Ikk   osteoclast 
progenitors by electrophoretic mobility shift assay using a  B site oligo-
nucleotide probe or a nuclear factor-y probe to control for loading and 
extract quality. (C) IKK activation by RANKL. Total protein lysates were 
prepared and IKK activity was measured by an immunocomplex kinase 
assay before and after RANKL stimulation of BM cells. I B (1–54) was 
used as a substrate. (D) Nuclear translocation of NF- B subunits. Osteo-
clast progenitors from WT, Ikk AA, and Ikk   mice were incubated with 
RANKL for the indicated durations in the presence of M-CSF. Nuclear (nuc) 
and cytoplasmic (cyt) extracts were analyzed by immunoblotting using anti-
bodies directed against NF- B family members and an anti–poly(ADP-ribose)-
polymerase antibody as a loading control. (E) p100 processing. Osteoclast 
progenitors from WT, Ikk AA, and Ikk   mice were incubated with RANKL 
for the indicated durations in the presence of M-CSF. Total protein 
extracts were analyzed for the presence of full-length p100 and its 
processed form, p52.IKK IN OSTEOCLASTOGENESIS | Ruocco et al. 1680
C); this is diagnostic of reduced osteoclast-mediated bone
resorption. The osteoclast parameters, number and surface,
are reduced significantly in Ikk   mice (Fig. 3 C). It also
seems that osteoblast number is reduced at 7 mo in the mu-
tant mice, a defect that was observed in other osteopetrotic
mouse models (35). The osteopetrotic phenotype of Ikk  
mice becomes more dramatic with age (Fig. 3 C). These re-
sults suggest that Ikk   mice develop osteopetrosis that is
due to defective osteoclast formation, and furthermore, indi-
cate a critical role for Ikk  in bone development.
Osteoblasts can rescue defective in vitro osteoclastogenesis 
of Ikk AA but not Ikk   BM cells
Osteoclasts also can be generated in vitro from BM hemato-
poietic precursors cultured in the presence of 1,25(OH)2-
vitamin D3 and dexamethasone together with osteoblastic/
stromal cells from mouse calvarias (36). In such a system, ac-
tivated osteoblasts play the major role in osteoclast differenti-
ation and provide M-CSF and RANKL directly. To exam-
ine whether the osteoclastogenic defects that are observed in
Ikk AA and Ikk   BM cultures are caused by cell autono-
mous defects, we performed osteoclasts/osteoblast cocul-
tures. Wt osteoblasts fully supported osteoclastogenesis of
Ikk AA osteoclast precursors, but not Ikk   osteoclast pre-
cursors; this indicates a cell–autonomous osteoclast differen-
tiation defect in Ikk   BM cells (Fig. 4 A, upper panels).
Reciprocal cocultures of Ikk AA or WT BM cells with
Ikk AA osteoblasts showed that Ikk AA osteoblasts had the
same capacity as WT osteoblasts for supporting osteoclast dif-
ferentiation (Fig. 4, A [lower panels] and B). Thus, Ikk AA
Figure 3. Ikk  , but not Ikk AA, mice are osteopetrotic. (A) Sections 
of the metaphyseal regions of the proximal tibia of 4-mo-old WT, Ikk AA, 
and Ikk   mice were subjected to H&E staining. (B) Decreased numbers of 
TRAP-positive (red-stained) multinucleated cells below the growth plate 
of Ikk   mice. TRAP-positive cells are marked by arrows. (C) Histomorpho-
metric analysis of structural bone parameters in Ikk   (n   6), Ikk AA 
(n   6), and F/F (Ikk F/F, n   6 ) mice at 4 and 7 mo of age. OcS/BS, osteo-
clast surface/bone surface; NOc/B.Pm, number of osteoclasts/bone perim-
eter/mm; Tr.Th, trabecular thickness (mm); Tr.N trabecular number/mm; 
Tr.S, trabecular separation/mm3; NOb/B.Pm, number of osteoblasts/bone 
perimeter/mm; ObS/BS, osteoblast surface/bone surface; MAR, mineral ap-
position rate. *P   0.05.
Figure 4. Osteoclastogenesis is impaired in Ikk  , but not in 
Ikk AA, BM cells that are cocultured with osteoblasts. (A) Equal 
numbers of BM cells from WT, Ikk AA, and Ikk   mice were plated in the 
presence of 5   105 cells/ml of primary calvarial osteoblasts (Ob) from WT 
or Ikk AA mice and cultured in the presence of 1,25(OH)2 vitamin D3 and 
dexamethasone for 6 d. Osteoclastogenesis was assayed by TRAP staining. 
(B) The extent of osteoclastogenesis (expressed as staining intensity 
 10 5) was determined by TRAP staining, quantified, and expressed as 
staining intensity  10 5.JEM VOL. 201, May 16, 2005 1681
ARTICLE
osteoclasts can form normally as long as they receive osteo-
blast-derived signals; this suggests that these signals compen-
sate for the defect in RANKL signaling.
IL-1 and TNF  rescue the osteoclastogenic defect of Ikk AA, 
but not Ikk   osteoclast progenitors
To identify potential signals that may compensate for the de-
fect in RANKL signaling of Ikk AA osteoclast precursors, we
examined the effect of the proinflammatory cytokines, IL-1
and TNF . IL-1 and TNF  are potent osteoclastogenic fac-
tors and are likely to be involved with RANKL in inflamma-
tion-induced bone loss (10, 37). We cultured osteoclast pro-
genitors from WT, Ikk AA, and Ikk   mice in the presence of
IL-1 or TNF , alone or together with RANKL. IL-1 and
TNF  strongly augmented the osteoclastogenic response of
WT BM to RANKL and led to the formation of numerous
TRAP-positive giant cells (Fig. 5 A). Either IL-1 or TNF ,
when combined with RANKL, completely rescued the os-
teoclastogenic defect of Ikk AA BM, although they did not
induce differentiation on their own (Fig. 5 A and not de-
picted). However, the defect in osteoclast differentiation of
Ikk   BM cultures could not be rescued by IL-1 or TNF 
(Fig. 5, A and B). The bone-resorbing activity of these cells
was assayed by an in vitro resorption pit assay and further
quantified. Ikk AA, but not Ikk  , BM cells were able to re-
sorb bone, once their differentiation defect was rescued by
IL-1 (not depicted) or TNF  (Fig. 5 C). Furthermore, we
found that when incubated with TNF , either in the absence
or presence of RANKL, most Ikk    osteoclast precursors
were dead within 48 h (Fig. 5 A). This prompted us to exam-
Figure 5. IL-1 or TNF  rescue RANKL-induced osteoclast differen-
tiation of Ikk AA, but not Ikk  , osteoclast progenitors. (A) Equal 
numbers of BM cells from WT, Ikk AA, Ikk  , and Ikk  :Tnfr1 /  mice were 
cultured in the presence of M-CSF (20 ng/ml) and RANKL (50 ng/ml) for
7 d. TNF  (20 ng/ml) or IL-1 (10 ng/ml) alone or in combination with RANKL 
were added. Osteoclastogenesis was assayed by TRAP staining. Incubation 
of Ikk   BM cells with TNF  resulted in death of all cells within 48 h. 
(B) Numbers of osteoclasts per field (%). Results shown are averages   SD 
(n   4). (C) The bone-resorbing activity of WT, Ikk AA, Ikk  , Tnfr1 / , and 
Ikk  :Tnfr1 /  osteoclasts was analyzed in vitro by quantification of 
resorption pit areas on calcium phosphate films. (D) TUNEL assay of BM 
cells from WT and Ikk   mice that were incubated for the indicated times 
with TNF  (1 ng/ml). (E) Quantification of the TUNEL assay results. The 
percentage of TUNEL positive cells in four representative fields was deter-
mined by cell counting. n.d., not depicted.IKK IN OSTEOCLASTOGENESIS | Ruocco et al. 1682
ine whether Ikk   BM cells undergo apoptosis in response
to TNF . Terminal deoxynucleotidyl transferase–mediated
dUTP nick-end labeling (TUNEL) assay revealed the appear-
ance of cells with distinct apoptotic morphology and frag-
mented DNA within 24 h of TNF  addition to Ikk   osteo-
clast precursors (Fig. 5, D and E). Very few such cells were
detected in cultures that were not exposed to TNF  or in
WT osteoclast precursors that were incubated with TNF .
Deletion of Tnfr1 rescues Ikk   osteoclast progenitors from 
TNF -induced apoptosis, but does not prevent osteopetrosis
TNFR1 contains a death domain and is capable of engaging
the apoptotic machinery (38). To further examine the
mechanism that underlies TNF -induced death of Ikk -
deficient preosteoclasts, we crossed Ikk   mice with Tnfr1 / 
mice to generate Ikk F/F:Mx1-Cre:Tnfr1 /  double mu-
tants. After poly(IC) injection, BM cultures that were
isolated from these mice were stimulated with RANKL
alone or with RANKL plus TNF ; osteoclast differentiation
was analyzed by TRAP staining. Loss of TNFR1 prevented
TNF -induced death of Ikk   osteoclast progenitors (Fig. 5
A, bottom). Furthermore, the absence of TNFR1 rescued
the inability of Ikk   cells to become TRAP-positive, but
did not allow them to differentiate fully into multinucleated
giant osteoclasts (Fig. 5 A) with the ability to resorb bone
(Fig. 5 C). Thus, IKK  is required for the prevention of
TNF -induced death and is needed for formation of fully
functional bone-resorbing osteoclasts.
Next we analyzed femurs of 4-mo-old WT, Ikk  ,
Tnfr1 / , and Ikk  :Tnfr1 / mice. Ikk  deletion in both
strains was induced as early as 9 d after birth. Histochemical
staining revealed osteopetrosis in Ikk  :Tnfr1 /  bones (Fig.
6 A). However, TRAP-positive cells could be detected eas-
ily in Ikk  :Tnfr1 /   mice, whereas they were scarce in
Ikk   mice (Fig. 6 B). Analysis of deoxypiridinoline cross-
links in urine samples—which reflects osteoclast activity in
vivo—revealed that in Ikk  :Tnfr1 /  mice, osteoclast re-
sorption activity remained severely attenuated, as in Ikk  
mice. Normal levels of deoxypiridinoline cross-links were
found in urine samples from Ikk AA or Tnfr1 /  mice.
Figure 6. Osteoclast precursors that lack IKK  are sensitive to 
TNF -mediated apoptosis. (A) Sections of the metaphyseal regions of 
femurs of 4-mo-old Tnfr1 /  and Ikk  :Tnfr1 /  mice were subjected to 
H&E staining. (B) TRAP staining of the metaphyseal regions of 4-mo-old 
WT, Ikk  , Tnfr1 / , and Ikk  :Tnfr1 /  mice. The numbers refer to osteo-
clasts per field. (C) Deoxypiridinoline (DPD) cross-links in the urine of WT, 
Ikk  , Tnfr1 / , and Ikk  :Tnfr1 / mice were measured as an indicator of 
in vivo osteoclast activity. The values were normalized for muscle creati-
nine that also is excreted in the urine to account for urine concentration 
(n   6). (D) H&E, F4/80 (red), and DAPI (blue) staining of sections from 
long bones of 4-mo-old WT, Ikk  , Tnfr1 / , and Ikk  :Tnfr1 /  mice. 
(E) F4/80 (red) and TUNEL (green) double staining and DAPI (blue) staining 
of sections from long bones of WT and Ikk   mice. (F) F4/80 staining of 
liver sections of WT and Ikk   mice.JEM VOL. 201, May 16, 2005 1683
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Immunohistochemical analyses by hematoxylin-eosin
(H&E) staining revealed a small number of osteoclast precur-
sors in the vicinity of the growth plate that were positive for
F4/80 staining in Ikk   mice, whereas many more such cells
were seen in WT mice (Fig. 6 D). Remarkably, the loss of
TNFR1 in Ikk  :Tnfr1 /  double mutant mice restored the
presence of F4/80 positive cells next to the growth plate
(Fig. 6 D). Double staining experiments revealed that in
Ikk   mice, most of the few F4/80-positive cells that were
present were apoptotic, based on TUNEL staining (Fig. 6
E). This further supports the hypothesis that the decreased
osteoclast number in Ikk   mice is due to increased apopto-
sis of their precursors. Control experiments showed that in
other tissues, such as the liver, the number of F4/80-positive
cells did not change in the absence of Ikk  (Fig. 6 F). De-
spite the decreased apoptosis of osteoclast precursors and res-
toration of TRAP-positive cells, the Ikk  :Tnfr1 /  double
mutant mice remain osteopetrotic. This suggests that osteo-
clasts that lack IKK  and TNFR1 are not fully functional
under basal conditions; this interpretation is consistent with
Figure 7. Lack of IKK  prevents inflammation-induced bone loss. 
2-mo-old WT (n   11), Ikk   (n   7), Tnfr1 /  (n   4), and Ikk  :Tnfr1 /  
(n   4) mice were injected once with LPS (500  g/ml) or saline control 
into the synovial space of their hind leg joints. (A) After 5 d the mice were 
killed and the limbs were fixed, decalcified, sectioned, and analyzed by 
H&E staining. The arrows show regions of bone loss. (B) Higher magnifica-
tion of the H&E staining of the joints of WT and Ikk   mice. B, bone; I, 
inflammation; S, synovial space. (C) The presence of osteoclasts (arrows) 
in WT and Ikk   mice that were treated with LPS was analyzed by TRAP 
staining. (D) F4/80 (red) and DAPI (blue) staining of sections from joints of 
WT and Ikk   mice that were treated with LPS. (E) Schematic model of 
RANKL and TNF  signaling during osteoclastogenesis and inflammation-
induced bone loss. X represents a pathway other than IKK/NF- B that is 
activated by RANKL binding to RANK and is essential for production of 
functional osteoclasts. This pathway is not activated by TNF  binding 
to TNFR1.IKK IN OSTEOCLASTOGENESIS | Ruocco et al. 1684
the severely reduced bone-resorbing activity in these mice
(Fig. 6 C).
Absence of IKK  protects mice from inflammation-induced 
bone loss, in a manner dependent on TNFR1
IKK  plays a crucial role in osteoclast differentiation under
physiologic conditions. We next analyzed whether IKK  or
IKK  is involved in inflammation-induced bone loss. We
used an established model of endotoxin-induced bone re-
sorption (39, 40). Ikk AA, Ikk  , Tnfr1 / , Ikk  :Tnfr1 / ,
and WT mice were injected with 500  g LPS in saline into
the synovial space of the hind limb knee joint, whereas the
contralateral knee was injected with saline alone; mice were
killed 5 d after injection. Ikk  deletion was induced 10 d be-
fore knee injection. Before sacrificing the mice, their ability
to move and flex their hind limb was assessed by video
cinematography (Videos 1 and 2, available at http://
www.jem.org/cgi/content/full/jem.20042081/DC1). The
staining of the joint bones (femurs and tibia) with H&E,
TRAP, and F4/80 showed a considerably lower number of
osteoclasts and osteoclast precursors in Ikk   mutant mice
compared with WT controls or Ikk AA mice (Fig. 7, A–D;
not depicted for Ikk AA). Although LPS-injected WT,
Ikk AA, and Tnfr1 /  mice completely lost the ability to flex
the hind limb, no such aberrations were evident in Ikk  
mice, which retained normal flexibility and movement of the
LPS-treated hind limb (Videos 1 and 2). The loss of TNFR1
restored inflammation-induced bone loss in mice that lack
Ikk   (Fig. 7), although the bone damage is not as extensive
as in WT mice (compare resorption sites indicated by arrows
in Fig. 7 A). The degree of inflammation-induced bone loss
was quite similar in Ikk  :Tnfr1 /  and Tnfr1 /  mice.
These results suggest that under strong inflammatory condi-
tions, which are likely to result in massive cytokine produc-
tion, IKK  is no longer needed for osteoclastogenesis once its
survival function has been rendered unnecessary by ablation
of TNFR1.
DISCUSSION
Previous studies that were based on ablation of the p50 and
p52 NF- B members outlined an important role for these
transcription factors in osteoclast differentiation (15). NF- B
is activated by RANKL, a cytokine whose expression and
binding to the receptor, RANK, are essential for osteoclas-
togenesis. NF- B also is activated by the proinflammatory
cytokines, TNF  and IL-1 (21), which enhance inflamma-
tion-induced bone loss, although they are not essential for
developmental osteoclastogenesis (41, 42). The activation of
NF- B by all of these cytokines depends on integrity of the
IKK complex (21); recent results show that a small peptide
that can prevent binding of the IKK  and IKK  catalytic
subunits to the IKK  regulatory subunit can inhibit inflam-
mation-induced bone loss (27). Although these results pro-
vide further support for the role of NF- B in osteoclastoge-
nesis, it has not been established which of the two IKK
catalytic subunits plays a more critical role in basal osteoclas-
togenesis and inflammation-induced bone loss. For instance,
it recently was described that the NIK- and IKK -depen-
dent alternative pathway is required for RANKL-induced
osteoclast differentiation in vitro (25). Our results demon-
strate a critical role for IKK , but not IKK , in basic osteo-
clastogenesis in vivo and in inflammation-induced bone loss.
Although IKK  and IKK  are important transducers of
osteoclastogenic signals which emanate from RANKL in
vitro, the mutation that prevents IKK  activation by its up-
stream kinase, NIK (23), had no effect on osteoclast forma-
tion in vivo and did not increase bone density. Furthermore,
Ikk AA mice were fully sensitive to inflammation-induced
bone loss (unpublished data). These results are consistent
with the small effect of the Ikk AA mutation on RANKL-
induced translocation of NF- B proteins to the nucleus, as
well as the absence of an osteopetrotic phenotype in mice
defective in NIK, the upstream activator of IKK  (25). Like
BM progenitors from Nik /  mice, Ikk AA BM progenitors
do not differentiate in response to RANKL when cultured
in the absence of osteoblasts. However, either osteoblasts or
the proinflammatory cytokines, IL-1  and TNF , together
with RANKL induce osteoclastogenesis of Ikk AA BM pro-
genitors. Thus, although IKK  contributes to RANKL-
induced differentiation in vitro, its function in vivo is dis-
pensable because of the action of other factors that activate
the IKK -driven classic NF- B pathway. During normal
bone development, these factors are likely to be derived
from osteoblasts, whereas during inflammation these factors
could be TNF  and IL-1 .
In contrast with IKK , our findings illustrate a critical
function for IKK . IKK -deficient BM progenitors do not
form osteoclasts in vitro in response to RANKL or when co-
cultured with osteoblasts. Furthermore, their inability to re-
spond to RANKL cannot be complemented by IL-1 or
TNF , and Ikk   mice are osteopetrotic. IKK -deficient
BM progenitors are extremely sensitive to TNF  and un-
dergo extensive apoptosis, despite the presence of the myeloid
survival factor, M-CSF. Because TNF -induced apoptosis of
IKK -deficient preosteoclasts is prevented by the loss of
TNFR1, we propose that one of the mechanisms by which
IKK -dependent NF- B activation contributes to osteoclas-
togenesis in vivo, especially during inflammation, is through
prevention of TNF -induced apoptosis of osteoclast progeni-
tors. In the absence of IKK , such cells become very sensitive
to TNF  and are eliminated when TNF  is produced in suf-
ficiently large amounts. Nonetheless, although the death of
Ikk -deficient osteoclast progenitors is prevented by loss of
TNFR1 and Ikk  :Tnfr1 /  double mutants display close to
normal numbers of TRAP-positive cells in their bones (Fig. 6
B), these mice become osteopetrotic (Fig. 6 A) if Ikk  dele-
tion is induced early during bone development. The explana-
tion for these results is that IKK -deficient osteoclasts remain
defective in bone resorption, even when their TNF -
induced elimination does not take place. Our in vitro resultsJEM VOL. 201, May 16, 2005 1685
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(Fig. 5 A) suggest that Ikk  :Tnfr1 /  progenitors cannot
give rise to fully differentiated osteoclasts, although they do
become TRAP-positive in response to RANKL. Morpho-
logically, such cells look like monocytes, rather than multinu-
cleated giant cells; this suggests that their ability to undergo
cell fusion is eliminated. Similar defects in basal osteoclast
functions were observed in Traf6 /  and Src /  mice (16, 43).
These mice are osteopetrotic as a result of the presence of os-
teoclasts that are unable to form ruffled borders, and therefore,
are defective in bone resorption.
Thus, in addition to the prevention of TNF -induced
apoptosis, IKK  is required for terminal osteoclast differenti-
ation. Although IKK -dependent NF- B activation is essen-
tial for this process, it is not sufficient; potent NF- B activat-
ing cytokines, such as TNF , cannot substitute for RANKL
(Fig. 7 E). Most likely, another pathway or factor, designated
X in Fig. 7 E, needs to be switched on—along with IKK 
and NF- B—for terminal osteoclast differentiation to take
place. Nonetheless, our results illustrate the potential ability
of IKK  inhibition to prevent inflammation-driven bone de-
struction. Again, the mechanism through which IKK  inhi-
bition prevents inflammation-induced bone loss involves
sensitization of osteoclast progenitors to TNF -induced
apoptosis, because Ikk  :Tnfr1 /  mice are fully susceptible
to inflammation-induced bone loss. The bone-resorbing abil-
ity of osteoclasts in Ikk  :Tnfr1 /  mice seems to be restored
after LPS injection. Because these cells do not respond to
TNF  (as a result of the loss of TNFR1), the inflammation-
induced factor that may stimulate their bone-resorbing activ-
ity could be IL-1 , which is known to be induced by LPS
administration (44). However, in vitro IL-1  is unable to in-
duce the formation of multinucleated bone-resorbing cells
when given together with RANKL once IKK  is absent
(Fig. 5 A). Alternatively, Ikk  :Tnfr1 /  osteoclast progeni-
tors may be only partially defective in their ability to respond
to RANKL; this defect may be eliminated when high levels
of RANKL are present along with other proinflammatory
cytokines. LPS-induced inflammation results in induction of
RANKL along with other cytokines (45).
Our results support a role for IKK  as an important reg-
ulator of bone homeostasis and a mediator of inflammation-
induced bone loss. Our results also suggest that the major
mechanism through which deletion or inhibition of IKK 
exerts its therapeutic effect in inflammation-induced bone
loss is by predisposing osteoclast precursors to TNF -
induced apoptosis. A schematic model that summarizes our
findings is presented in Fig. 7 E. Binding of RANKL to its
receptor, RANK, induces a cascade of events that leads to
activation of IKK  and at least one more factor—that to-
gether with IKK —is required for induction of terminal os-
teoclast differentiation. During inflammation, proinflamma-
tory cytokines, such as TNF  and IL-1 , are induced and
strongly potentiate RANKL-induced osteoclastogenesis, al-
though such factors cannot induce osteoclast differentiation
on their own. TNF  signaling through TNFR1 has the po-
tential to induce apoptosis through caspase 8, a process that is
prevented by IKK -dependent NF- B activation (46).
Once IKK  is inhibited, TNF -induced apoptosis results in
elimination of Ikk -deficient osteoclast progenitors, and
thereby, prevents inflammation-induced bone destruction.
Thus, IKK  inhibition presents a logical strategy for preven-
tion of numerous bone-resorbing disorders that are triggered
by inflammation, such as rheumatoid arthritis.
MATERIALS AND METHODS
Mice. Ikk AA and Ikk F/F mice were generated as described (29, 32). To
delete IKK  in hematopoietic cells, Ikk F/F mice were crossed with Mx1-
Cre transgenic mice (33), and Ikk F/F:Mx1-Cre progeny were injected three
times with poly(IC) every 2 d. Injections started at day 9 after birth for in
vivo analysis, whereas injections were performed 10 d before killing mice or
collecting BM cells, respectively. Deletion of Ikk  was confirmed by PCR,
whereas the absence of IKK  protein was examined by immunoblotting.
These mice are referred to as Ikk   mice. All experimental procedures were
approved by the Animal Subjects Committee at the University of California
San Diego, according to U.S. National Institutes of Health guidelines.
Histologic and histomorphometric analyses. Tissues were fixed in
PBS-buffered 4% formaldehyde, embedded in paraffin, sectioned at 5  m,
and stained as indicated using standard techniques. Calcified tissues were de-
calcified in EDTA (0.5 M, pH 8) for 12 d before embedding. TRAP stain-
ing was performed using a leukocyte acid phosphatase kit (Sigma-Aldrich).
For histomorphometry, tibiae were embedded in methacrylate (Echnovit;
Heraeus Kulzer) without previous decalcification and 3–4- m sections
were stained with Goldner trichrome. Histomorphometry of metaphyses
was performed using an Axioskop 2 microscope (Carl Zeiss MicroImaging,
Inc.) and OsteoMeasure Analysis System (OsteoMetrics) according to inter-
national standards (47). TUNEL assay and immunohistochemistry were as
described previously (48, 49).
Osteoclast culture and activity assay. BM cells from 6-wk-old mice
were plated in the presence of 5 ng/ml recombinant M-CSF for 24 h Non-
adherent cells were replated in the presence of recombinant M-CSF (10 ng/
ml) and recombinant-RANKL (50 ng/ml) for 7 d and then fixed and
stained for TRAP activity. For biochemical analysis, BM cells were plated
in the presence of M-CSF (10 ng/ml) for 6 d, collected, and counted. Os-
teoclast activity was assayed in vitro after differentiation on a calcium phos-
phate film (BioCoat Bone Cell Culture System, Osteologic) and the re-
sorpted area was quantified using AxioVision 4.3 software. Osteoclast
activity in vitro was measured in urine samples using RatLaps ELISA (Nor-
dic Bioscience Diagnostics).
Osteoblast–osteoclast cocultures. Primary osteoblasts were isolated
from calvarias of neonatal (2–4-d-old) WT and Ikk AA mice and were di-
gested for 10 min in modified Eagle’s medium ( -MEM) which contained
0.1% collagenase and 0.2% dispase. Cells from two to five mice were com-
bined as an osteoblastic cell population and plated at a density of 5   105
cells/ml in  -MEM with 10% FCS for 24 h. Cocultures were performed as
described (36, 50). Briefly, BM cells (106 per well) were added to primary
osteoblasts (5   105 cells per well) and cultured in  -MEM which con-
tained 10% FCS, 10 8 M 1,25(OH)2-vitamin D3, and 10 7 M dexametha-
sone in 24-well plates. Intensity of TRAP staining was measured by Image
Pro Plus 5.1.
Subcellular fractionation and immunoblot analysis. Cells were re-
suspended in buffer L1 (50 mM Tris-Cl, pH 8.0, 2 mM EDTA, 0.1% NP-
40, 10% glycerol) that contained protease inhibitors, incubated for 5 min at
4 C, and centrifuged for 5 min at 4,000 revolutions/min in a microcentri-
fuge. Cytoplasmic supernatants were stored and nuclear pellets were ex-IKK IN OSTEOCLASTOGENESIS | Ruocco et al. 1686
tracted further in buffer L2 (20 mM Hepes-KOH, pH 7.6, 150 mM NaCl,
2 mM EDTA, 1% Triton X-100, 10% glycerol, 25 mM  -glycerophos-
phate) which contained protease inhibitors. After lysis, nuclei were centri-
fuged at 15,000 revolutions/min and the supernatant was collected for fur-
ther analysis. Nuclear (5  g) and cytoplasmic (20  g) extracts were
electrophoresed, transferred to nitrocellulose membranes, and immunoblot-
ted with anti-IKK  (Imgenex), anti-IKK  (UBI), anti-RelA, anti-RelB,
and anti-c-Rel (Santa Cruz Biotechnology, Inc.) antibodies. p100 process-
ing in total extracts was assayed using anti–NF- B/p52 K-27 antibody
(Santa Cruz Biotechnology, Inc.).
IKK and gel shift assays. IKK immunocomplex kinase assay was as de-
scribed (51), except that an IKK  antibody (BD Biosciences) was used for
immunoprecipitation. Electrophoretic mobility shift assay for NF- B was
described previously (23).
Inflammation-induced bone loss. 2- to 3-mo-old mice were given an
intrajoint injection of Escherichia coli LPS (Sigma-Aldrich), 500  g in saline,
and a vehicle control into the contralateral joint, 5 d after the last poly(IC)
treatment. 5 d later, mice were killed and joint histology was examined in
the Histologic and histomorphometric analyses section.
Statistical analysis. Data are expressed as mean   SEM. Differences were
analyzed by Student’s t test.
Online supplemental material. Ikk F/F (Video 1) and Ikk   (Video 2)
mice were given an intrajoint injection of E. coli LPS (Sigma-Aldrich), 500
 g in saline, (left hind limb) and a vehicle control (right hind limb). The
two videos show the ability of the mice to move and stretch their hind
limbs. Online supplemental material is available at http://www.jem.org/
cgi/content/full/jem.20042081/DC1.
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